HIV-positive men at higher risk for Heart Disease
Formation of plaques is more frequent in coronary arteries of HIV positive men than HIV negative men, according to a new study by National Institutes of Health grantees. The research describes that HIV-infected men are at higher risk for a heart attack than their HIV-uninfected which is published in Annals of Internal Medicine.
Fixed Dose Combinations (FDCs) manufacturers are invited to present their proposal for approval of the safety and efficacy of permitted for manufacture for sale in the country without due approval from office of Drug Controller General of India (DCGI).
On thursday, 27th march 2014, the World Health Organisation (WHO) presented official certification to India for its ‘Polio Free’ status. India is among other countries in its South East Asian region which have been certified as being free of the wild polio virus. Ghulam Nabi Azad, health minister of India, received the official certificate from WHO. 
The U.S. Food and Drug Administration approved the first implantable device for people 18 and older with severe or profound sensorineural hearing loss of high-frequency sounds in both ears, but who can still hear low-frequency sounds with or without a hearing aid. The Nucleus Hybrid L24 Cochlear Implant System may help those with this specific kind of hearing loss who do not benefit from conventional hearing aids.
New findings, by group of scientists, will facilitate the development of new clinical strategies design to prevent or treat infections caused by multidrug-resistant Klebsiella Pneumoniae. 
The Drugs and Cosmetics Rules, 1945 (D&C rules) were amended vide Drugs and Cosmetics (Fourth Amendment) Rules, 2013 published under Gazette notification G.S.R. 588(E) dated 30.08.2013 regarding the inclusion of Schedule H1 under the D&C rules containing certain antibiotics, anti-TB drugs and habit forming drugs. The notification states that these rules will come into force after six months of their publication in the official Gazette i.e. from 1st March, 2014
Indian health ministry revoked the ban from Analgin, potent analgesic and antipyretic. Last year in June 2013, government issued a ban on manufacturing and selling of analgin in country because it is involved in risk to human beings and whereas safer alternatives of analgin are available. After revoking ban from pioglitazone, this is the second time when ministry has lifted ban from a drug.
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
